Waystar (WAY) Q1 2026 Earnings Call Transcript

Waystar reported Q1 revenue of $314 million, up 22% year over year, with adjusted EBITDA rising 26% to $135 million and margin at 43%. Management reaffirmed full-year guidance for revenue of $1.274 billion-$1.294 billion and adjusted EBITDA of $530 million-$540 million, while highlighting that AI-powered solutions drove 40% of new bookings and nearly 40% of revenue. The main offset was softness in patient payment solutions from accelerated print-to-digital conversion and healthcare utilization headwinds, but the company also improved net leverage to 2.7x and received debt rating upgrades.

Analysis

The setup is less about this quarter’s beat and more about a multi-year mix shift: Waystar is gradually converting a low-multiple, volume-sensitive business into a higher-multiple software/automation compounder. The second-order effect is that AI is not just a feature bundle; it is broadening the addressable market into labor substitution, which can re-rate the stock if investors start underwriting revenue-cycle automation instead of pure transaction processing. That matters because the market will likely underappreciate how quickly a larger deal pipeline can convert into deferred revenue visibility even if reported growth looks choppy over the next 1-2 quarters.

The near-term bear case is the mix drag from patient-payment volumes, but that is also the cleanest tell on quality of demand: the headwind appears operationally benign and margin-neutral, while provider solutions keep compounding faster and at better economics. In other words, the top line may decelerate mechanically before the incremental gross profit does, which can create an attractive entry point if the market extrapolates Q2 flat-to-up-1% sequential growth too literally. The bigger risk is not competition today; it is execution on implementation timing, because bigger platform deals stretching 6-18 months can create a “good bookings, slower revenue” period that tests investor patience.

Credit upgrade and leverage improvement reduce equity risk, but they also make the story more investable for crossover buyers who were previously blocked by balance-sheet optics. The most interesting contrarian angle is that digital statement migration is being treated as a headwind, yet it likely improves lifetime economics and lowers servicing costs, which should flow through to FCF and margin quality over time. If management sustains high win rates and early AI adoption converts into tangible ARR-like recurring workflows, the stock can grind higher even without a near-term acceleration in reported growth.

Key Decisions for Investors

• Long WAY on any post-earnings consolidation or if the stock sells off on Q2 sequential-growth fears; target 3-6 month horizon, with upside from multiple expansion as AI-driven workflow revenue is recognized as higher-quality recurring software.
• Use a call spread in WAY 6-12 months out to express the thesis that bookings convert slower than headline revenue but still drive a 2027 re-rate; risk/reward favors upside if the market starts pricing autonomous revenue-cycle labor displacement.
• Pair trade: long WAY / short a lower-quality healthcare transaction processor or payments name with weaker software mix, to isolate the mix-shift toward embedded AI workflows and away from commoditized volume.
• If available, buy WAY on weakness after the market overreacts to patient-payment softness; the risk is limited if bookings and pipeline remain strong, while the catalyst is an Analyst Day / next two quarters of implementation conversion evidence.
• Avoid chasing after a strong gap up unless management commentary confirms faster monetization of new AI SKUs; otherwise the better entry is when investors focus too much on temporary volume noise and not enough on backlog quality.